DUBLIN–(BUSINESS WIRE)–The “Global Chronic Obstructive Pulmonary Disease Drugs Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
The chronic obstructive pulmonary disease drugs market is poised to grow by $5.63 bn during 2021-2025, progressing at a CAGR of 5.68%
The market is driven by the rising prevalence of COPD, strong pipeline and new drug approvals, and the growing demand for fixed-dose combinations.
The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The chronic obstructive pulmonary disease drugs market analysis includes the product segment and geographic landscape.
This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and the growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, SHIONOGI Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, and Viatris Inc.
Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Key Topics Covered:
Executive Summary
- Market overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 – 2025
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Combination therapy – Market size and forecast 2020-2025
- Monotherapy – Market size and forecast 2020-2025
- Market opportunity by Product
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Exela Pharma Sciences LLC
- GlaxoSmithKline Plc
- Merck and Co. Inc.
- Novartis AG
- SHIONOGI Co. Ltd.
- Sumitomo Dainippon Pharma Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/3m3t0q
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900